Relevant to this study, treatment of KRASG12C lung cancer cells with sotorasib has been shown to induce the increased expression of AURKA, which then directly interacted with KRASG12C, locking KRAS into an active, KRASG12C inhibitor–insensitive state (51). Here, KRAS is linked to lung carcinoma.